Table 3 Results of subgroup analysis among included studies
From: A meta-analysis of the impact of COVID-19 on liver dysfunction
Subgroup | Studies sample size | Included (N) (study/control) | Chi-square (df) | P value | Pooled overall heterogeneity | SMD (95% CI) (I2) |
|---|---|---|---|---|---|---|
Non-survivors vs survivors ALS (levels) | ||||||
Age≥70 | 2 | 86/432 | 0.72 (1) | .001 | 3.25 (2.95-3.56) | 0 |
Severe vs non-severe ALT (levels) | ||||||
Number of non-severe≥100 | 2 | 115/364 | 0.06 (1) | .001 | 3.42 (3.12-3.73) | 0 |
Severe vs non-severe AST (events) | ||||||
Age≥60 | 6 | 379/1284 | 11.17 (5) | .001 | 5.09 (3.26-7.94) | 55 |
Severe vs non-severe AST (levels) | ||||||
Age≥60 | 3 | 81/236 | 2.21 (2) | .001 | 3.98 (3.54-4.43) | 10 |
Severe vs non-severe TBIL (levels) | ||||||
Number of non-severe≥100 | 2 | 88/364 | 0.62 (1) | .001 | 1.49 (1.24-1.74) | 0 |
Number of non-severe<100 | 4 | 125/236 | 5.14 (3) | .001 | 0.93 (0.61-1.25) | 42 |